Cullinan Associates Inc. Buys 7,900 Shares of Sanofi (NYSE:SNY)
Cullinan Associates Inc. boosted its position in Sanofi (NYSE:SNY) by 12.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,900 shares of the company’s stock after buying an additional 7,900 shares during the period. Cullinan Associates Inc.’s holdings in Sanofi were worth $3,445,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox bought a new position in shares of Sanofi during the fourth quarter valued at approximately $2,770,485,000. Fisher Asset Management LLC increased its stake in shares of Sanofi by 1.0% in the first quarter. Fisher Asset Management LLC now owns 12,615,505 shares of the company’s stock valued at $570,852,000 after buying an additional 123,470 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the last quarter. Finally, Brandes Investment Partners LP increased its stake in shares of Sanofi by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock valued at $157,933,000 after buying an additional 102,511 shares during the last quarter. Hedge funds and other institutional investors own 9.97% of the company’s stock.
Sanofi (SNY) opened at 48.08 on Monday. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The firm has a market capitalization of $120.75 billion, a price-to-earnings ratio of 11.54 and a beta of 0.88. The stock’s 50 day moving average price is $48.11 and its 200 day moving average price is $45.82.
Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post $3.23 earnings per share for the current fiscal year.
Several research analysts recently commented on SNY shares. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research report on Tuesday, April 11th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Argus lifted their price objective on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Finally, Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.